← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Sodium-glucose co-transporter 2 (SGLT2) inhibitors
ipragliflozin
A10BK05
Forms & Strengths
- Oral tablets: 50 mg
- Oral tablets: 75 mg
Adult Dosing
- Type 2 Diabetes Mellitus: 50 mg orally once daily in the morning
- May be increased to 75 mg orally once daily if glycemic control is insufficient
Pediatric Dosing
- Safety and effectiveness in pediatric patients below 18 years of age have not been established
Indications
- Improvement of glycemic control in type 2 diabetes mellitus
Mechanism of Action
- Sodium-glucose cotransporter 2 (SGLT2) inhibitor
- Inhibits SGLT2 in the proximal renal tubules, reducing renal reabsorption of filtered glucose
- Lowers renal threshold for glucose, increasing urinary glucose excretion (glucosuria) and reducing blood glucose levels
Contraindications
- History of serious hypersensitivity reaction to ipragliflozin
- Severe renal impairment (eGFR < 30 mL/min/1.73m2), end-stage renal disease, or patients on dialysis
- Type 1 diabetes mellitus
Adverse Reactions
- Hypoglycemia (especially when combined with insulin or sulfonylureas)
- Genitourinary infections (vulvovaginal candidiasis, urinary tract infections)
- Pollakiuria (increased urination)
- Volume depletion, dehydration, and hypotension
- Diabetic ketoacidosis (rare)
- Increased serum creatinine and lipid elevations
Drug Interactions
- Antidiabetic agents (insulin, sulfonylureas, glinides): increased risk of hypoglycemia; dose reduction of these agents may be required
- Diuretics: may potentiate the risk of volume depletion and hypotension
Curated Content: Needs Vetting Before Put to Clinical Use